WEBULL

A Fresh Look at Exact Sciences (EXAS): Is the Current Valuation Attractive for Investors?

Simply Wall St · 09/24/2025 16:37

Should Investors Take a Fresh Look at Exact Sciences?

Exact Sciences (EXAS) has caught investors’ attention after a recent move in its share price, prompting questions about whether the company’s outlook is shifting or if there is a signal worth noting. While there is no single event triggering the current headlines, the stock’s movement is sparking fresh interest among those watching the diagnostics space, especially for anyone weighing their holdings as the healthcare landscape evolves.

It’s been a mixed year for Exact Sciences. The stock dipped roughly 24% over the past twelve months, despite posting around 10% growth this month. Earlier momentum from a three-year stretch of strong gains appears to be slowing, as more recent returns have been flat. Recent company updates and steady revenue growth hint at opportunities, but volatility is giving investors a reason to pause.

So, after all the ups and downs, is Exact Sciences trading at an attractive entry point or is the market already factoring in any future growth?

Most Popular Narrative: 18.1% Undervalued

According to the most widely followed view, Exact Sciences is trading below its estimated fair value, with analysts projecting significant upside potential from current levels.

"Accelerated adoption of preventative diagnostics and personalized medicine by providers and patients is fueling higher screening rates, as evidenced by record physician engagement, robust rescreen rates, and digital ordering growth. This should further drive revenue and margin expansion as Exact's test suite gains share."

Want to know why analysts are betting on Exact Sciences? Find out which growth rates and profit leaps are fueling such a bullish outlook. The full narrative reveals the powerful drivers and bold projections behind this valuation call. There is more under the hood than just market optimism. See how ambitious future assumptions play into this story.

Result: Fair Value of $64.01 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, risks remain, including heavy reliance on Cologuard and rising competition in cancer screening. These factors could challenge Exact Sciences' growth story going forward.

Find out about the key risks to this Exact Sciences narrative.

Another View: Discounted Cash Flow Model

Looking from another angle, our DCF model supports the case that Exact Sciences is undervalued. This suggests its long-term cash flow prospects are more optimistic than current market pricing. Which approach do you trust more?

Look into how the SWS DCF model arrives at its fair value.
EXAS Discounted Cash Flow as at Sep 2025
EXAS Discounted Cash Flow as at Sep 2025
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Exact Sciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Exact Sciences Narrative

If you are not convinced by these perspectives or would rather draw your own conclusions, you can analyze the data and build a custom story in just a few minutes. Do it your way.

A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Exact Sciences.

Looking for More Smart Investment Opportunities?

Stay ahead of the curve by searching out innovative stocks and fresh market trends using the Simply Wall St Screener. Miss out and you could be leaving strong returns on the table while others step in.

  • Spot companies at the forefront of artificial intelligence by tapping into AI penny stocks, and capture tomorrow’s tech winners today.
  • Strengthen your income strategy and find growth with stability by uncovering dividend stocks with yields > 3% offering reliable yields and robust financials.
  • Catch undervalued gems flying under the radar through undervalued stocks based on cash flows, so you never miss a potential bargain before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.